Regulus Therapeutics Inc

NASDAQ:RGLS  
0.23
+0.02 (+7.90%)
Products

Regulus Therapeutics Announces FDA Acceptance Of IND Application For RGLS8429 For Treatment Of ADPKD

Published: 05/11/2022 12:22 GMT
Regulus Therapeutics Inc (RGLS) - Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (ind) Application for Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd).
Regulus Therapeutics Inc - Company Remains on Track to Initiate Phase 1 Clinical Study in Q2 2022.